Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608551 | 0.95 | LMNA (0.44) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL9609271 | 0.90 | POLB (0.54) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL12754989 | 0.87 | CYP1A2 (0.46) | POLBLMNATSHRADORA3ALOX15 | |
| SCHEMBL18267897 | 0.82 | L3MBTL1 (0.48) | POLBLMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL12250342 | 0.82 | NPC1 (0.45) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL9608549 | 0.82 | LMNA (0.47) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL9608484 | 0.81 | POLB (0.55) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL9608470 | 0.81 | CHUK (0.55) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL9609240 | 0.81 | NPC1 (0.49) | POLBLMNAHSD17B10TSHRADORA3 | |
| SCHEMBL9609235 | 0.80 | NOTUM (0.48) | POLBLMNATSHRADORA3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957140-B2 | Triazine derivative, ultraviolet absorber, and resin composition | FUJIFILM CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8748520-B2 | Polycarbonate resin composition containing triazine compound and molded article using the same | FUJIFILM CORPORATION (JP) | 2014-06-10 | — | — | US | disclosed |
| US-8623990-B2 | Polyester resin composition | FUJIFILM CORPORATION (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120301696-A1 | POLYESTER RESIN COMPOSITION | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120136098-A1 | NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | FUJIFILM CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110077331-A1 | POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME | FUJIFILM CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136098-A1 | NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | C1R, RPSA, H1-2 | POLB 246/4885LMNA 1414/4885HSD17B10 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.